Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12759058 | 0.95 | HSD17B10 (0.32) | HSD17B10 | |
| SCHEMBL10106991 | 0.90 | ALDH1A1 (0.35) | HSD17B10 | |
| SCHEMBL15375170 | 0.83 | TSHR (0.44) | CES1CA1CA2 | |
| SCHEMBL469014 | 0.82 | ALDH1A1 (0.37) | HSD17B10 | |
| SCHEMBL12760550 | 0.82 | ALDH1A1 (0.37) | HSD17B10 | |
| SCHEMBL12759071 | 0.81 | — | — | |
| SCHEMBL19866145 | 0.80 | — | — | |
| SCHEMBL13165938 | 0.79 | CES1 (0.53) | CES1CA1CA2 | |
| SCHEMBL12141358 | 0.79 | ALDH1A1 (0.34) | — | |
| SCHEMBL12759069 | 0.79 | ALDH1A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340000-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | HONGENE BIOTECH CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-11692001-B2 | Functionalized n-acetylgalactosamine analogs | HONGENE BIOTECH CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-20150196655-A1 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2015-07-16 | — | — | US | disclosed |
| US-7932326-B2 | Chelating compounds and immobilized tethered chelators | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340000-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | FUT6, CSGALNACT1, GALNT6 | HSD17B10 3264/4885CES1 1480/4885CA1 2423/4885 |
| US-11692001-B2 | Functionalized n-acetylgalactosamine analogs | FUT6, CSGALNACT1, GALNT6 | HSD17B10 3264/4885CES1 1480/4885CA1 2423/4885 |
| US-20150196655-A1 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION | RNASE1, IGF2BP1, IGF2BP2 | HSD17B10 2672/4885CES1 1325/4885CA1 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.